Moderna, Regeneron warn about the effectiveness of COVID-19 drugs, vaccines against the omicron variant Owlet pulls baby-monitoring Smart Sock from market after FDA warning The top 10 healthcare M&A targets in 2022 GlaxoSmithKline poaches Pfizer vax leader Dormitzer after hemorrhaging vaccine R&D talent Biogen takes another blow as appeal for Tecfidera patent revival falls short After flunking key trial, Deciphera cuts 140 jobs, halts development of two drugs Bristol Myers Squibb's next-gen autoimmune med starts high-stakes FDA review amid classwide JAK scrutiny Hyperfine’s portable MRI nets FDA clearance for deep learning-powered imaging RAGE against diabetes complications: Novel drug tamps down tissue damage in mice 'What it takes': As Lilly's Alzheimer's drug approaches FDA, launch leader feels 'amplified' sense of excitement UnitedHealth Group expects at least $317B in revenue for 2022 Federal judge halts CMS' COVID-19 vaccine mandate for healthcare workers in 10 rural states TG tumbles as FDA still hasn’t found what its looking for in U2 leukemia combo, orders advisory committee Insilico Medicine begins first human trial of its AI-designed drug for pulmonary fibrosis Featured Story | By Kevin Dunleavy As the world assesses the threat posed by the COVID-19 omicron variant, two top companies producing pandemic drugs and vaccines have warned that their current offerings may not be effective against the variant. read more |
| |
|---|
|
| | The PerkinElmer Lead Discovery Premium Biotech Bundle empowers you to find and understand trends and outliers in your data to ensure successful candidate selection. On the AWS Cloud, affordable, easy to deploy. Learn more. |
Top Stories By Andrea Park Owlet is no longer selling its Smart Sock vital sign monitors for babies and toddlers after the FDA informed the company that the devices had been improperly brought to market. read more By Heather Landi Early in 2020, there was a massive pandemic-induced nosedive in merger and acquisitions deals in healthcare. But the industry rapidly rebounded, and the pace accelerated in 2021. In this report, we’ll take you through some companies that could be in the M&A crosshairs during 2022, such as digital pharmacies and health systems. read more By Ben Adams GlaxoSmithKline has seen a host of vaccine research staffers exit the Big Pharma over the past year, but it’s hoping a big name can get its vaccine business back on track. read more By Fraiser Kansteiner A U.S. appeals court has declined to resurrect a key patent on Biogen’s once-stalwart multiple sclerosis med Tecfidera, according to court documents filed Tuesday. It’s the latest spot of trouble for the struggling blockbuster, which succumbed to its first generic competitor last summer. read more By Kevin Dunleavy A devastating trial flop for its gastrointestinal cancer drug Qinlock has prompted Deciphera to undergo a transformation. The biopharma will cut 140 jobs, reducing its headcount by 35%. Deciphera also will abandon its development of Qinlock and ovarian cancer candidate, rebastinib. read more By Angus Liu After the FDA slapped an updated safety warning on marketed oral JAK inhibitors for inflammatory diseases, market watchers have started worrying about other candidates in the pipeline. Bristol Myers Squibb now has a date to learn how the agency views its novel medicine deucravacitinib, with blockbuster sales at stake. read more By Conor Hale The portable MRI machine maker Hyperfine obtained a new clearance from the FDA, adding deep-learning algorithms that can boost the quality of images taken by its scanner-on-wheels. read more By Arlene Weintraub NYU researchers have developed a drug that prevent a protein called rage from triggering inflammatory signals in diabetes. The drug reduced the risk of heart attack and sped up the healing of diabetic wounds in mouse models of diabetes. read more By Annalee Armstrong Fierce Biotech profiles three women breaking barriers in Alzheimer's disease R&D at leading pharmaceutical companies. Today, Eli Lilly's donanemab launch leader Brandy Matthews. read more By Paige Minemyer UnitedHealth will host its annual investor conference Tuesday morning, and the healthcare giant updated its outlook for 2021 ahead of the meeting. read more By Dave Muoio The preliminary injunction is an early win for the 22 rural and red states that have filed challenges against CMS' COVID-19 vaccine requirement for healthcare workers. read more By Annalee Armstrong The FDA still hasn't found what its looking for in TG Therapeutics’ application for the leukemia and lymphoma combo treatment nicknamed U2, and so the therapy will be examined at an advisory committee meeting. read more By Conor Hale The former Fierce 15 winner announced that the first healthy volunteer in an Australian study has received a limited, intravenous dose of the company’s ISM001-055, a small-molecule inhibitor aimed at the chronic lung disease. read more | 